2,379 results on '"Kumada, Hiromitsu"'
Search Results
102. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma
103. The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection
104. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C
105. Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment
106. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay
107. Histological impact at 5 years after the start of sodium-glucose cotransporter 2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus
108. Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage
109. Renal safety and biochemical changes for two years of tenofovir alafenamide after switching from long‐term other nucleotide analogues treatment in patients with chronic hepatitis B
110. Comparison between Lumipulse Presto HBsAg-HQ and iTACT-HBsAgin Chronic Hepatitis B with Seroclearance of HBsAg by Architect HBsAg QT
111. High Virus Titer, Slow Virus Decrease, Genotype II, and Sequence Variability of E2/NS1 HVR Predict Poor Response to Interferon Therapy in Chronic Hepatitis C
112. Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine
113. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
114. In Hepatocellular Carcinomas, any Proportion of Poorly Differentiated Components is Associated with Poor Prognosis After Hepatectomy
115. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up
116. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B
117. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials
118. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
119. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
120. Clinicopathological indices to predict hepatocellular carcinoma molecular classification
121. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients
122. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis
123. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
124. ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy—A Genome-Wide Study of Japanese HCV Virus Patients
125. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir
126. Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
127. Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
128. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration
129. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan
130. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
131. Randomized Trial of Interferon- and Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir in Treatment-Experienced Hepatitis C Virus–Infected Patients
132. HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy
133. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b
134. Potential impact of joint association of alanine aminotransferase and gamma-glutamyltransferase on insulin resistance in Japan: The Toranomon Hospital Health Management Center Study 19 (TOPICS 19)
135. Implication of an extremely high preoperative alpha-fetoprotein value (>4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma
136. A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C
137. ゲノタイプ2/1組み換えC型肝炎ウイルス感染患者3例に対して奏功した直接作用型抗ウイルス剤投与
138. Additional file 2 of Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study
139. Additional file 1 of Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study
140. Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study
141. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study
142. Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers
143. Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients
144. Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers
145. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis
146. Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
147. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma
148. Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy
149. Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
150. Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.